TransCode Therapeutics (RNAZ) Competitors $0.54 +0.06 (+12.27%) (As of 12:50 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNAZ vs. TPST, NXTC, OKYO, RVPH, LTRN, ALBT, PASG, MRKR, TRVN, and LUMOShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Tempest Therapeutics (TPST), NextCure (NXTC), OKYO Pharma (OKYO), Reviva Pharmaceuticals (RVPH), Lantern Pharma (LTRN), Avalon GloboCare (ALBT), Passage Bio (PASG), Marker Therapeutics (MRKR), Trevena (TRVN), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Tempest Therapeutics NextCure OKYO Pharma Reviva Pharmaceuticals Lantern Pharma Avalon GloboCare Passage Bio Marker Therapeutics Trevena Lumos Pharma Tempest Therapeutics (NASDAQ:TPST) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership. Does the MarketBeat Community prefer TPST or RNAZ? Tempest Therapeutics received 86 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 91.67% of users gave TransCode Therapeutics an outperform vote while only 65.10% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes9765.10% Underperform Votes5234.90% TransCode TherapeuticsOutperform Votes1191.67% Underperform Votes18.33% Which has more volatility & risk, TPST or RNAZ? Tempest Therapeutics has a beta of -1.78, suggesting that its share price is 278% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Which has preferable earnings & valuation, TPST or RNAZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$1.60-0.56TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Does the media prefer TPST or RNAZ? In the previous week, Tempest Therapeutics' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score. Company Overall Sentiment Tempest Therapeutics Neutral TransCode Therapeutics Neutral Is TPST or RNAZ more profitable? Tempest Therapeutics' return on equity of -201.10% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -201.10% -78.32% TransCode Therapeutics N/A -597.48%-260.31% Do insiders and institutionals have more ownership in TPST or RNAZ? 22.5% of Tempest Therapeutics shares are held by institutional investors. 3.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 0.2% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate TPST or RNAZ? Tempest Therapeutics currently has a consensus price target of $20.75, suggesting a potential upside of 2,215.85%. TransCode Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 493.47%. Given Tempest Therapeutics' higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than TransCode Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTempest Therapeutics beats TransCode Therapeutics on 7 of the 10 factors compared between the two stocks. Ad Porter & CompanyCentral banks prepare for America’s Breaking PointIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.83M$6.73B$5.01B$8.44BDividend YieldN/A7.94%7.49%4.16%P/E RatioN/A11.44125.4316.59Price / SalesN/A285.221,649.4776.80Price / CashN/A46.0936.9033.53Price / Book0.205.244.575.20Net Income-$18.55M$150.36M$113.24M$223.59M7 Day Performance-14.37%0.00%113.23%3.82%1 Month Performance-13.25%16.13%127.64%9.53%1 Year Performance-96.40%36.64%156.55%29.35% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.2522 of 5 stars$0.54+12.3%$3.00+456.7%-96.6%$9.31MN/A0.009Gap UpTPSTTempest Therapeutics2.2292 of 5 stars$1.16+5.0%$20.75+1,696.5%-75.3%$25.66MN/A-0.7220Gap UpNXTCNextCure3.8635 of 5 stars$1.39+1.8%$6.00+333.2%+12.7%$38.75MN/A-0.6390Upcoming EarningsPositive NewsGap UpOKYOOKYO Pharma3.3456 of 5 stars$1.13-0.9%$7.00+519.5%-33.3%$38.24MN/A0.007RVPHReviva Pharmaceuticals1.9558 of 5 stars$1.14-5.0%$14.33+1,157.3%-79.9%$38.12MN/A-0.885Positive NewsLTRNLantern Pharma1.048 of 5 stars$3.54-3.3%N/A+15.3%$38.09MN/A-2.1520Positive NewsALBTAvalon GloboCare0.4668 of 5 stars$3.41-20.7%N/A-70.7%$37.87M$1.30M-2.535Gap DownPASGPassage Bio2.6214 of 5 stars$0.61-8.1%$8.33+1,263.9%-4.1%$37.66MN/A-0.45130Upcoming EarningsMRKRMarker Therapeutics3.5444 of 5 stars$4.13-4.4%$19.00+360.0%+16.6%$36.85M$3.31M0.0060TRVNTrevena1.3405 of 5 stars$1.97-4.8%$125.00+6,245.2%-87.7%$36.13M$443,000.00-0.0440Analyst ForecastLUMOLumos Pharma3.259 of 5 stars$4.37-1.8%$8.63+97.4%+25.2%$35.48M$2.05M-0.9930Upcoming Earnings Related Companies and Tools Related Companies Tempest Therapeutics Competitors NextCure Competitors OKYO Pharma Competitors Reviva Pharmaceuticals Competitors Lantern Pharma Competitors Avalon GloboCare Competitors Passage Bio Competitors Marker Therapeutics Competitors Trevena Competitors Lumos Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNAZ) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts